Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P134 cells in recurrent glioblastoma
NCT07318818Phase 2Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in glioblastoma (GBM), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Dose limiting toxicities at 28 days, Adverse events at 2.5 years and 1 more. Started Jan 2026; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07318818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318818.